Active visfatin is elevated in serum of maintenance haemodialysis patients and correlates inversely with circulating HDL cholesterol

Nephrology Dialysis Transplantation

Volumn 24, Issue 9, 2009, Pages 2832-2838

  Nüsken, Kai Dietrich ^a   Petrasch, Maurice ^a   Rauh, Manfred ^a   Stöhr, Wolfgang ^a   Nüsken, Eva ^a   Schneider, Holm ^a   Dötsch, Jörg ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Body composition; Diabetes; End stage renal disease; HDL cholesterol; Visfatin

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE;

ADULT; ARTICLE; BODY COMPOSITION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HEMODIALYSIS; HUMAN; INSULIN BLOOD LEVEL; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PARAMETER; PRIORITY JOURNAL; SKINFOLD THICKNESS; WAIST CIRCUMFERENCE;

AGED; BODY COMPOSITION; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; REGRESSION ANALYSIS; RENAL DIALYSIS; RISK FACTORS;

EID: 69249130434     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp178     Document Type: Article

References (37)

1. Fukuhara A, Matsuda M, Nishizawa M et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-430
2. Revollo JR, K̈orner A,Mills KF et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NADbiosynthetic enzyme. Cell Metab 2007; 6: 363-375
3. Haider DG, Schindler K, Schaller G et al. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006; 91: 1578-1581
4. Chen MP, Chung FM, Chang DM et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91: 295-299
5. López-Bermejo A, Chico-Julìa B, Ferǹandez-Balsells M et al. Serum visfatin increases with progressive beta-cell deterioration. Diabetes 2006; 55: 2871-2875
6. Krzyzanowska K, Krugluger W, Mittermayer F et al. Increased visfatin concentrations in women with gestational diabetes mellitus. Clin Sci (Lond) 2006; 110: 605-609
7. Berndt J, Kl̈oting N, Kralisch S et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54: 2911-2916
8. Haider DG, Schaller G, Kapiotis S et al. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 2006; 49: 1909-1914
9. Pagano C, Pilon C, Olivieri M et al. Reduced plasma visfatin/pre B-cell colony enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 2006; 91: 3165-3170
10. Chan TF, Chen YL, Lee CH et al. Decreased plasma visfatin concentrations in women with gestational diabetes mellitus. J Soc Gynecol Investig 2006; 13: 364-367
11. Axelsson J, Witasp A, Carrero JJ et al. Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am J Kidney Dis 2007; 49: 237-244
12. Yilmaz MI, Saglam M, Carrero JJ et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant 2008; 23: 959-965
13. Yilmaz MI, Saglam M, Qureshi AR et al. Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial Transplant 2008; 23: 1621-1627
14. N̈usken KD, N̈usken E, Petrasch M et al. Preanalytical influences on the measurement of visfatin by enzyme immuno assay. Clin Chim Acta 2007; 382: 154-156
15. K̈orner A, Garten A, Bl̈uher M et al. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 2007; 92: 4783-4791
16. Retnakaran R, Youn BS, Liu Y et al. Correlation of circulating fulllength visfatin (PBEF/Nampt) with metabolic parameters in subjects with and without diabetes: a cross-sectional study. Clin Endocrinol (Oxf) 2008; 69: 885-893
17. N̈usken KD, Petrasch M, Rauh M et al. Reduced plasma visfatin in end-stage renal disease is associated with reduced body fat mass and elevated serum insulin. Exp Clin Endocrinol Diabetes 2007; 115: S29 (Abstract)
18. Ziegelmeier M, Bachmann A, Seeger J et al. Adipokines influencing metabolic and cardiovascular disease are differentially regulated in maintenance hemodialysis. Metabolism 2008; 57: 1414-1421
19. Rongvaux A, Shea RJ, Mulks MH et al. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol 2002; 32: 3225-3234
20. Yang H, Yang T, Baur JA et al. Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell 2007; 130: 1095-1107
21. Barter P, Gotto AM, LaRosa JC et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357: 1301-1310
22. Gordon T, Castelli WP, Hjortland MC et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62: 707-714
23. Jordao AA, Bellucci AD, Dutra de Oliveira JE et al. Midarm computerized tomography fat, muscle and total areas correlation with nutritional assessment data. Int J Obes Relat Metab Disord 2004; 28: 1451-1455
24. Di Iorio BR, Scalfi L, Terracciano V et al. A systematic evaluation of bioelectrical impedance measurement after hemodialysis session. Kidney Int 2004; 65: 2435-2440
25. Chertow GM, Lowrie EG, Wilmore DW et al. Nutritional assessment with bioelectrical impedance analysis in maintenance hemodialysis patients. J Am Soc Nephrol 1995; 6: 75-81
26. Zoccali C, Mallamaci F, Tripepi G et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 134-141
27. N̈usken KD, Wienholz V, Sẗohr W et al. Circulating resistin concentrations in children depend on renal function. Nephrol Dial Transplant 2006; 21: 107-112
28. Herbelin A, Urẽna P, Nguyen AT et al. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int 1991; 39: 954-960
29. de Mutsert R, Grootendorst DC, Axelsson J et al. NECOSAD Study Group. Excess mortality due to interaction between proteinenergy wasting, inflammation and cardiovascular disease in chronic dialysis patients. Nephrol Dial Transplant 2008; 23: 2957-2964
30. Zhong M, TanHW, Gong HP et al. Increased serumvisfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol (Oxf) 2008; 69: 878-884
31. Díez JJ, Iglesias P, Fernández-Reyes MJ et al. Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease. Clin Endocrinol (Oxf) 2005; 62: 242-249
32. Bae SK, Kim SR, Kim JG et al. Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1. FEBS Lett 2006; 580: 4105-4113
33. Lim SY, Davidson SM, Paramanathan AJ et al. The novel adipocytokine visfatin exerts direct cardioprotective effects. J Cell Mol Med 2008; 12: 1395-1403
34. Moschen AR, Kaser A, Enrich B et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 17: 1748-1758
35. Beddhu S, Pappas LM, Ramkumar N et al. Effects of body size and body composition on survival in hemodialysis patients. J Am Soc Nephrol 2003; 14: 2366-2372
36. M̈auser W, Perwitz N, Meier B et al. Direct adipotropic actions of atorvastatin: differentiation state-dependent induction of apoptosis, modulation of endocrine function, and inhibition of glucose uptake. Eur J Pharmacol 2007; 564: 37-46
37. Storka A, Vojtassakova E, Mueller M et al. Angiotensin inhibition stimulates PPARgamma and the release of visfatin. Eur J Clin Invest 2008; 38: 820-826